
|Articles|June 11, 2014
DrFirst, My Vision Express partner to deliver comprehensive e-Rx to ECPs
DrFirst and My Vision Express recently partnered to integrate Rcopia e-prescribing into My Vision Express Electronic Health Record and Practice Management system for eyecare practitioners (ECPs).
Advertisement
Weston, FL-DrFirst and My Vision Express recently partnered to integrate Rcopia e-prescribing into My Vision Express Electronic Health Record and Practice Management system for eyecare practitioners (ECPs).
With the addition of Rcopia e-prescribing, ECPs will be able to access patient information, including drug and allergy interactions, available prescribing history, and formulary information, and securely submit electronic prescriptions to retail or mail-order pharmacies.
Next:
Advertisement
Related to this article

Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

The school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

Will AI reinvent the way patients book appointments in the next 5 years? Raphael Rostenne weighs in in the season 2 finale of The Independent Advantage.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada
2
High Point University optometry school earns ACOE preliminary approval
3
Alice Epitropoulos, MD, on phentolamine for presbyopia treatment
4
Polygenic risk flags patients likely to need more glaucoma treatment
5


